Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S&N gains exclusive rights to Acticoat dressing in $21m buy

This article was originally published in Clinica

Executive Summary

Smith & Nephew’s advanced wound management subsidiary has gained full control of the Acticoat antimicrobial barrier dressings range after the firm purchased the product’s manufacturer Nucryst Pharmaceuticals. Previously, S&N exclusively licensed the product from Nucryst. As part of the acquisition, S&N will acquire Nucryst’s Fort Saskatchewan, Canada-based operations and intellectual property related to the dressing for $21m. The Acticoat dressing utilises Nucryst’s Silcryst nanocrystalline silver coating technology and offers bacterial reduction, fluid management and sustained release of silver ions. It has a non-adherent design. Nucryst ran into trouble earlier this year when it received a notice from the Nasdaq that it was not in compliance with the exchange’s rules after it had traded at below $1.00 per share for more than 30 days.

You may also be interested in...

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials

Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts